s4nchez
New Member
Thank you bro itsa wonderful info
MESO-Rx
Anabolic Steroids
Hair Loss
- Thread starter billydidit
- Start date
hankmoody
New Member
I have had the same problem, except I am prone to male pattern baldness. I take saw palmetto and it has been very effective at stopping my hair loss
Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: an evidence-based review. Lasers Med Sci. Low level laser therapy and hair regrowth: an evidence-based review - Online First - Springer
Despite the current treatment options for different types of alopecia, there is a need for more effective management options. Recently, low-level laser therapy (LLLT) was evaluated for stimulating hair growth. Here, we reviewed the current evidence on the LLLT effects with an evidence-based approach, focusing more on randomized controlled studies by critically evaluating them. In order to investigate whether in individuals presenting with hair loss (male pattern hair loss (MPHL), female pattern hair loss (FPHL), alopecia areata (AA), and chemotherapy-induced alopecia (CIA)) LLLT is effective for hair regrowth, several databases including PubMed, Google Scholar, Medline, Embase, and Cochrane Database were searched using the following keywords: Alopecia, Hair loss, Hair growth, Low level laser therapy, Low level light therapy, Low energy laser irradiation, and Photobiomodulation. From the searches, 21 relevant studies were summarized in this review including 2 in vitro, 7 animal, and 12 clinical studies. Among clinical studies, only five were randomized controlled trials (RCTs), which evaluated LLLT effect on male and female pattern hair loss. The RCTs were critically appraised using the created checklist according to the Critical Appraisal for Therapy Articles Worksheet created by the Center of Evidence-Based Medicine, Oxford. The results demonstrated that all the performed RCTs have moderate to high quality of evidence. However, only one out of five studies performed intention-to-treat analysis, and only another study reported the method of randomization and subsequent concealment of allocation clearly; all other studies did not include this very important information in their reports. None of these studies reported the treatment effect of factors such as number needed to treat. Based on this review on all the available evidence about effect of LLLT in alopecia, we found that the FDA-cleared LLLT devices are both safe and effective in patients with MPHL and FPHL who did not respond or were not tolerant to standard treatments. Future randomized controlled trials of LLLT are strongly encouraged to be conducted and reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement to facilitate analysis and comparison.
Despite the current treatment options for different types of alopecia, there is a need for more effective management options. Recently, low-level laser therapy (LLLT) was evaluated for stimulating hair growth. Here, we reviewed the current evidence on the LLLT effects with an evidence-based approach, focusing more on randomized controlled studies by critically evaluating them. In order to investigate whether in individuals presenting with hair loss (male pattern hair loss (MPHL), female pattern hair loss (FPHL), alopecia areata (AA), and chemotherapy-induced alopecia (CIA)) LLLT is effective for hair regrowth, several databases including PubMed, Google Scholar, Medline, Embase, and Cochrane Database were searched using the following keywords: Alopecia, Hair loss, Hair growth, Low level laser therapy, Low level light therapy, Low energy laser irradiation, and Photobiomodulation. From the searches, 21 relevant studies were summarized in this review including 2 in vitro, 7 animal, and 12 clinical studies. Among clinical studies, only five were randomized controlled trials (RCTs), which evaluated LLLT effect on male and female pattern hair loss. The RCTs were critically appraised using the created checklist according to the Critical Appraisal for Therapy Articles Worksheet created by the Center of Evidence-Based Medicine, Oxford. The results demonstrated that all the performed RCTs have moderate to high quality of evidence. However, only one out of five studies performed intention-to-treat analysis, and only another study reported the method of randomization and subsequent concealment of allocation clearly; all other studies did not include this very important information in their reports. None of these studies reported the treatment effect of factors such as number needed to treat. Based on this review on all the available evidence about effect of LLLT in alopecia, we found that the FDA-cleared LLLT devices are both safe and effective in patients with MPHL and FPHL who did not respond or were not tolerant to standard treatments. Future randomized controlled trials of LLLT are strongly encouraged to be conducted and reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement to facilitate analysis and comparison.
You want to lose more hair? A razor will increase loss of hair.
haha no, just wondering since I plan on taking a blocker. And I figure women have more estrogen and I'm probably over simplifying it.
SkinnyPunk
New Member
Bro,
Is this just for on-cycle or off cycle too? Are there any toxicity issues for long term?
Is this just for on-cycle or off cycle too? Are there any toxicity issues for long term?
[Open Access] Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us?
Androgenetic alopecia (AGA) is a highly heritable condition, and the most common form of hair loss in men.
The phenotype is characterized by an androgen-dependent, progressive loss of hair from the scalp, which may commence during puberty.
Up to 80% of European men experience some degree of androgen-dependent hair loss during their lifetime.
Current treatment options for AGA have limited efficacy, and improved understanding of the underlying biological causes is required to facilitate novel therapeutic approaches.
To date, molecular genetic studies have implicated 12 genomic regions in AGA, and identified a number of candidate genes.
The latter include those encoding the androgen receptor (AR); the histone-deacetylases (HDAC) 4 and 9; and the WNT-molecule WNT10A. However, the majority of contributing genetic risk factors still await identification.
This review describes the current status of AGA genetic research. We discuss the strength of the genetic approach and anticipated developments in the field, and how these will facilitate the systematic unravelling of AGA pathobiology, a process which may lead to the identification of new therapeutic targets.
Heilmann-Heimbach S, Hochfeld LM, Paus R, Nothen MM. Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? Exp Dermatol. Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? - Heilmann-Heimbach - Experimental Dermatology - Wiley Online Library
Androgenetic alopecia (AGA) is a highly heritable condition, and the most common form of hair loss in men.
The phenotype is characterized by an androgen-dependent, progressive loss of hair from the scalp, which may commence during puberty.
Up to 80% of European men experience some degree of androgen-dependent hair loss during their lifetime.
Current treatment options for AGA have limited efficacy, and improved understanding of the underlying biological causes is required to facilitate novel therapeutic approaches.
To date, molecular genetic studies have implicated 12 genomic regions in AGA, and identified a number of candidate genes.
The latter include those encoding the androgen receptor (AR); the histone-deacetylases (HDAC) 4 and 9; and the WNT-molecule WNT10A. However, the majority of contributing genetic risk factors still await identification.
This review describes the current status of AGA genetic research. We discuss the strength of the genetic approach and anticipated developments in the field, and how these will facilitate the systematic unravelling of AGA pathobiology, a process which may lead to the identification of new therapeutic targets.
Heilmann-Heimbach S, Hochfeld LM, Paus R, Nothen MM. Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? Exp Dermatol. Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? - Heilmann-Heimbach - Experimental Dermatology - Wiley Online Library
[Open Access] Young Man with Unexplained Hair Loss [Secondary Syphilis]
A 21-year-old man sought care at our dermatology clinic because he was concerned about the patchy hair loss on his scalp that had begun 4 months earlier (FIGURE). His primary care physician had prescribed topical antifungals for presumed seborrheic dermatitis with no effect.
Three months prior to his visit with us, the patient had also seen his primary care physician for a nonspecific exanthema. It was presumed to be a viral exanthem and spontaneously resolved.
The pattern of the alopecia and a closer look at his history provided valuable diagnostic clues.
Kinard J, Tieu K, Kimmer S. Young man with unexplained hair loss. J Fam Pract 2015;64(12):801-3. http://www.jfponline.com/?id=21643&tx_ttnews[tt_news]=457505&cHash=0a0b7a59789bcb3c38f4493e7eceeded
A 21-year-old man sought care at our dermatology clinic because he was concerned about the patchy hair loss on his scalp that had begun 4 months earlier (FIGURE). His primary care physician had prescribed topical antifungals for presumed seborrheic dermatitis with no effect.
Three months prior to his visit with us, the patient had also seen his primary care physician for a nonspecific exanthema. It was presumed to be a viral exanthem and spontaneously resolved.
The pattern of the alopecia and a closer look at his history provided valuable diagnostic clues.
Kinard J, Tieu K, Kimmer S. Young man with unexplained hair loss. J Fam Pract 2015;64(12):801-3. http://www.jfponline.com/?id=21643&tx_ttnews[tt_news]=457505&cHash=0a0b7a59789bcb3c38f4493e7eceeded
Can Longshot RepliCel Replicate Success?
Biotech Watcher: Can Longshot RepliCel Replicate Success?
RepliCel Life Sciences (OTCQB: REPCF) is an early stage biotech that uses regenerative cells from the patient’s hair follicle to treat pattern baldness (AKA androgenetic alopecia); chronic tendinosis (AKA tendinopathy, tendinitis); and skin wrinkles especially sun-damaged skin.
Investigators have completed early proof-of-concept trials in alopecia and tendinosis. The current set of proof of concept trials will give important clues to the viability of its technologies.
The financial summary is scary and it’s a penny stock. Why even watch RepliCel?
Biotech Watcher: Can Longshot RepliCel Replicate Success?
RepliCel Life Sciences (OTCQB: REPCF) is an early stage biotech that uses regenerative cells from the patient’s hair follicle to treat pattern baldness (AKA androgenetic alopecia); chronic tendinosis (AKA tendinopathy, tendinitis); and skin wrinkles especially sun-damaged skin.
Investigators have completed early proof-of-concept trials in alopecia and tendinosis. The current set of proof of concept trials will give important clues to the viability of its technologies.
The financial summary is scary and it’s a penny stock. Why even watch RepliCel?
Spooby
Member
Where do you get dutasteride??
Bernard BA. Advances in Understanding Hair Growth. F1000Res 2016;5. Advances in Understanding Hair Growth - F1000Research
In this short review, I introduce an integrated vision of human hair follicle behavior and describe opposing influences that control hair follicle homeostasis, from morphogenesis to hair cycling. The interdependence and complementary roles of these influences allow us to propose that the hair follicle is a true paradigm of a "Yin Yang" type, that is a cold/slow-hot/fast duality. Moreover, a new promising field is emerging, suggesting that glycans are key elements of hair follicle growth control.
In this short review, I introduce an integrated vision of human hair follicle behavior and describe opposing influences that control hair follicle homeostasis, from morphogenesis to hair cycling. The interdependence and complementary roles of these influences allow us to propose that the hair follicle is a true paradigm of a "Yin Yang" type, that is a cold/slow-hot/fast duality. Moreover, a new promising field is emerging, suggesting that glycans are key elements of hair follicle growth control.
Sulforaphane Promotes Murine Hair Growth By Accelerating The Degradation Of Dihydrotestosterone
Highlights
· Sulforaphane is a novel candidate for the treatment of androgenic alopecia.
· Sulforaphane improves androgenic alopecia by lowering the plasma dihydrotestosterone concentration.
· The induction of hepatic 3α-HSD by sulforaphane leads to the degradation of dihydrotestosterone.
Sasaki M, Shinozaki S, Shimokado K. Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone. Biochem Biophys Res Commun. Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone
Dihydrotestosterone (DHT) causes the regression of human hair follicles in the parietal scalp, leading to androgenic alopecia (AGA).
Sulforaphane (SFN) increases the expression of DHT degrading enzymes, such as 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs), and, therefore, SFN treatment may improve AGA.
To determine the effects of SFN on hair growth, we administered SFN (10 mg/kg BW, IP) or vehicle (DMSO) to ob/ob mice for six weeks and examined hair regeneration and the plasma levels of testosterone and DHT.
We also tested the effects of SFN on the expression of two forms of 3alpha-HSD, aldo-keto reductase 1c21 and dehydrogenase/reductase (SDR family) member 9, both in vitro and in vivo.
SNF significantly enhanced hair regeneration in ob/ob mice.
The mice treated with SFN showed lower plasma levels of testosterone and DHT than those treated with vehicle.
SFN increased the mRNA and protein levels of the two forms of 3alpha-HSD in the liver of the mice and in cultured murine hepatocyte Hepa1c1c7 cells.
These results suggest that SFN treatment increases the amount of 3alpha-HSDs in the liver, accelerates the degradation of blood DHT, and subsequently blocks the suppression of hair growth by DHT.
Highlights
· Sulforaphane is a novel candidate for the treatment of androgenic alopecia.
· Sulforaphane improves androgenic alopecia by lowering the plasma dihydrotestosterone concentration.
· The induction of hepatic 3α-HSD by sulforaphane leads to the degradation of dihydrotestosterone.
Sasaki M, Shinozaki S, Shimokado K. Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone. Biochem Biophys Res Commun. Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone
Dihydrotestosterone (DHT) causes the regression of human hair follicles in the parietal scalp, leading to androgenic alopecia (AGA).
Sulforaphane (SFN) increases the expression of DHT degrading enzymes, such as 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs), and, therefore, SFN treatment may improve AGA.
To determine the effects of SFN on hair growth, we administered SFN (10 mg/kg BW, IP) or vehicle (DMSO) to ob/ob mice for six weeks and examined hair regeneration and the plasma levels of testosterone and DHT.
We also tested the effects of SFN on the expression of two forms of 3alpha-HSD, aldo-keto reductase 1c21 and dehydrogenase/reductase (SDR family) member 9, both in vitro and in vivo.
SNF significantly enhanced hair regeneration in ob/ob mice.
The mice treated with SFN showed lower plasma levels of testosterone and DHT than those treated with vehicle.
SFN increased the mRNA and protein levels of the two forms of 3alpha-HSD in the liver of the mice and in cultured murine hepatocyte Hepa1c1c7 cells.
These results suggest that SFN treatment increases the amount of 3alpha-HSDs in the liver, accelerates the degradation of blood DHT, and subsequently blocks the suppression of hair growth by DHT.
[Open Access] Guidelines On The Use Of Finasteride In Androgenetic Alopecia
BACKGROUND: Finasteride is a widely used drug in dermatology for the treatment of androgenetic alopecia. There are many reports of associated sexual side effects. This article reviews the use of once-daily 1 mg finasteride in androgenetic alopecia and its associated sexual adverse effects.
METHODS: A literature search was performed to collect data on the use of finasteride in male pattern baldness. Relevant literature published till March 2014 was obtained from MEDLINE, EMBASE, CINAHL, Cochrane registers and LILACS. The keywords "finasteride", "male pattern baldness" and "androgenetic alopecia" were used for literature search. Similarly, a search was done for finasteride in female pattern hair loss with keywords "female pattern baldness", "finasteride" and "female pattern alopecia". All systematic reviews, meta-analyses, national guidelines, randomized controlled trials, prospective open label studies and retrospective case series in the English literature were reviewed.
RESULTS: Two hundred sixty two studies were evaluated, twelve of which fulfilled the inclusion criteria.
CONCLUSIONS AND RECOMMENDATIONS: Current evidence on the safety of finasteride indicates that it is safe but there is growing concern about its sexual side effects. In view of this, proper information should be provided to patients prior to starting treatment (Level of recommendation 1+, Grade of recommendation B). The reported sexual side effects are few and reverse with stoppage of the drug (Grade of recommendation B) but further studies are required.
Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol 2016;82(2):128-34. http://www.ijdvl.com/article.asp?issn=0378-6323;year=2016;volume=82;issue=2;spage=128;epage=134;aulast=Mysore (Guidelines on the use of finasteride in androgenetic alopecia Mysore V, Shashikumar B M - Indian J Dermatol Venereol Leprol)
BACKGROUND: Finasteride is a widely used drug in dermatology for the treatment of androgenetic alopecia. There are many reports of associated sexual side effects. This article reviews the use of once-daily 1 mg finasteride in androgenetic alopecia and its associated sexual adverse effects.
METHODS: A literature search was performed to collect data on the use of finasteride in male pattern baldness. Relevant literature published till March 2014 was obtained from MEDLINE, EMBASE, CINAHL, Cochrane registers and LILACS. The keywords "finasteride", "male pattern baldness" and "androgenetic alopecia" were used for literature search. Similarly, a search was done for finasteride in female pattern hair loss with keywords "female pattern baldness", "finasteride" and "female pattern alopecia". All systematic reviews, meta-analyses, national guidelines, randomized controlled trials, prospective open label studies and retrospective case series in the English literature were reviewed.
RESULTS: Two hundred sixty two studies were evaluated, twelve of which fulfilled the inclusion criteria.
CONCLUSIONS AND RECOMMENDATIONS: Current evidence on the safety of finasteride indicates that it is safe but there is growing concern about its sexual side effects. In view of this, proper information should be provided to patients prior to starting treatment (Level of recommendation 1+, Grade of recommendation B). The reported sexual side effects are few and reverse with stoppage of the drug (Grade of recommendation B) but further studies are required.
Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol 2016;82(2):128-34. http://www.ijdvl.com/article.asp?issn=0378-6323;year=2016;volume=82;issue=2;spage=128;epage=134;aulast=Mysore (Guidelines on the use of finasteride in androgenetic alopecia Mysore V, Shashikumar B M - Indian J Dermatol Venereol Leprol)
Alves R, Grimalt R. Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia. Dermatol Surg 2016;42(4):491-7. Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia. - PubMed - NCBI
BACKGROUND: Platelet-rich plasma (PRP) was identified as having a beneficial effect in alopecia and has been postulated as a new therapy for androgenetic alopecia (AGA).
OBJECTIVE: To assess the efficacy of PRP for the treatment of AGA.
MATERIALS AND METHODS: This was a randomized, placebo-controlled, double-blind study in 25 patients with AGA. Platelet-rich plasma was injected in half-head and the other half-head with placebo. Each patient received a total of 3 treatments of PRP, 1 month apart.
RESULTS: Six months after the first treatment with PRP, significant differences were seen in mean anagen hairs (67.6 +/- 13.1), telogen hairs (32.4 +/- 13.1), hair density (179.9 +/- 62.7), and terminal hair density (165.8 +/- 56.8) when compared with baseline (p < .05). Platelet-rich plasma was also found to increase hair density when comparing with the control side (p < .05). For the first time, the authors found a correlation between anagen hairs and patients >40 years and beginning of AGA >/=25 years old (p < .05) and hair density and male sex, age </=40 years, positive family history of AGA and >10 years of duration of the disease (p < 0.05).
CONCLUSION: Application of PRP showed a positive effect on AGA and could be regarded as an adjuvant therapy for AGA.
BACKGROUND: Platelet-rich plasma (PRP) was identified as having a beneficial effect in alopecia and has been postulated as a new therapy for androgenetic alopecia (AGA).
OBJECTIVE: To assess the efficacy of PRP for the treatment of AGA.
MATERIALS AND METHODS: This was a randomized, placebo-controlled, double-blind study in 25 patients with AGA. Platelet-rich plasma was injected in half-head and the other half-head with placebo. Each patient received a total of 3 treatments of PRP, 1 month apart.
RESULTS: Six months after the first treatment with PRP, significant differences were seen in mean anagen hairs (67.6 +/- 13.1), telogen hairs (32.4 +/- 13.1), hair density (179.9 +/- 62.7), and terminal hair density (165.8 +/- 56.8) when compared with baseline (p < .05). Platelet-rich plasma was also found to increase hair density when comparing with the control side (p < .05). For the first time, the authors found a correlation between anagen hairs and patients >40 years and beginning of AGA >/=25 years old (p < .05) and hair density and male sex, age </=40 years, positive family history of AGA and >10 years of duration of the disease (p < 0.05).
CONCLUSION: Application of PRP showed a positive effect on AGA and could be regarded as an adjuvant therapy for AGA.
[Open Access] Androgenetic Alopecia. Modelling Progression and Regrowth
Androgenetic alopecia(AGA) produces the phenotypes of male pattern hair loss and female pattern hair loss.
The pathogenesis of AGA involves hair follicle miniaturization and changes to the hair cycle.
Hair follicle miniaturization involves conversion of terminal hairs into secondary vellus hairs.
This is recognized in scalp biopsies and phototrichograms as a reduction in the number of terminal hairs per cm2 and an increase in the number of vellus hairs per cm2 .
In addition, a small reduction in the total number of hair follicles detectable on scalp biopsy occurs with advancing age.
Sinclair R. Androgenetic Alopecia. Modelling Progression and regrowth. Exp Dermatol. Androgenetic Alopecia. Modelling Progression and regrowth - Sinclair - Experimental Dermatology - Wiley Online Library
Androgenetic alopecia(AGA) produces the phenotypes of male pattern hair loss and female pattern hair loss.
The pathogenesis of AGA involves hair follicle miniaturization and changes to the hair cycle.
Hair follicle miniaturization involves conversion of terminal hairs into secondary vellus hairs.
This is recognized in scalp biopsies and phototrichograms as a reduction in the number of terminal hairs per cm2 and an increase in the number of vellus hairs per cm2 .
In addition, a small reduction in the total number of hair follicles detectable on scalp biopsy occurs with advancing age.
Sinclair R. Androgenetic Alopecia. Modelling Progression and regrowth. Exp Dermatol. Androgenetic Alopecia. Modelling Progression and regrowth - Sinclair - Experimental Dermatology - Wiley Online Library
Bc physiologic enzymes are highly specific for ONE particular compound,
I believe the larger question is to what extent do AAS "DHT analogs" or DHT metabolites interact with the follicular androgen receptor.
IFyour predisposed to MPB chances are the use of 5ARIs medications will only influence the effect of TT/DHT on the hair follicle while ANY other AAS will worsen hair loss.
Last edited:
Similar threads
